AUPH - Aurinia Pharma GAAP EPS of -$0.08 beats by $0.11 revenue of $41.49M beats by $3.98M
2023-08-03 06:02:12 ET
- Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11 .
- Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M .
- Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ® (voclosporin).
For further details see:
Aurinia Pharma GAAP EPS of -$0.08 beats by $0.11, revenue of $41.49M beats by $3.98M